首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 421 毫秒
1.
报告了测定2-重氮-1-萘醌-5-磺酰氯含量的光度分析的联立方程法。无水乙醇溶液中,分别在3725、407nm波长处测定吸光度,建立联立方程式,通过解联立方程计算出215-磺酰氯含量。平均回收率为10016%,相对标准偏差为069%。  相似文献   

2.
报告了紫外分光光度法测定2-重氮-1-萘醌-5-磺酸含量的方法,水溶液中,波长为407nm时,2-40μg/ml2-重氮-1-萘醌-5-磺酸与吸光度成直线关第。相关系数为0.99998,平均回收率为101.37%,相对标准偏差为0.745%。  相似文献   

3.
温占华  徐宁 《沈阳化工》1998,27(3):11-12,16
报告了测定2-重氮-1-萘醌-5-磺酰氯含量的光度分析的联立方程法。无水乙醇溶液中,分别在372.5,407nm波长处测定吸光度,建立联立方程式,通过解联立方程计算出2.1.5-磺酰氯含量。  相似文献   

4.
2-重氮-1-萘醌-5-磺酰氯是合成PS版感光胶的主要感光剂,本文中主要探讨了2,1,5c含水量及光照后,在室温条件下贮存对其含量和熔点的影响。  相似文献   

5.
王芬  刘彧  明霞 《化学世界》2005,46(6):362-364
以1萘酚5磺酸和亚硝酸钠为原料,经亚硝化、还原、重氮化和氯磺化反应,生成2重氮1萘醌5磺酰氯的合成工艺,讨论了关键反应的影响因素及检测方法。产物的紫外测定波长为372.5nm时,在4~30μg mL范围内与吸光度成良好的线性关系,相关系数γ=0.9999,摩尔吸收系数1.5×105L mol·cm,平均回收率为100.30%,相对标准偏差为0.42%。  相似文献   

6.
本文阐述了1,2-萘醌-2-重氮基-5-磺酰氯的生产和废水处理,并通过络合萃取法进行废水处理,回收了原料1,2-萘醌-2-重氮基-5-磺酸钠。  相似文献   

7.
阳图PS版用重氮萘醌系感光组成物研究进展   总被引:1,自引:0,他引:1  
目前PS版在印刷领域仍占有较重要地位,重氮萘醌系感光组成物自20世纪应用以来,经久不衰。文章主要介绍了PS版用重氮萘醌系感光组成物的研究进展情况,包括重氮类感光化合物,与之配合使用的版基、成膜树脂、酯化体。同时产酸剂、背景染料、溶剂及其它添加剂简单进行了归纳,并研究了重氮萘醌系阳图PS版的配方化学及发展趋势。  相似文献   

8.
重氮萘醌体系阳图PS版因具有感度高、上墨快、显影简单、环保以及储存稳定性好等特点,一直在印刷领域处于重要地位。随着印刷业的发展,还应进一步提高阳图PS版的感度,提高耐溶剂(异丙醇)性、耐印力。本文主要介绍了一种新型的用于阳图PS版的重氮萘醌系感光剂的合成方法和其成像性能的研究。这种感光剂是由6,7-二羟基-3,3-二苯基-3H-苯并呋喃-2-酮作为酯化母体,按照一定的摩尔比与2,1,5-重氮萘醌磺酰氯进行酯化反应制得。它与线性酚醛树脂、有机溶剂等成分组成配方。通过配方实验对这种新型感光剂的成像性能进行了研究,发现其不仅显影宽容度大,而且具有较高的感度,较好的抗碱留膜率和耐溶剂性能,良好的分辨率,并对其作为PS版感光剂的应用前景进行了评价。  相似文献   

9.
酚醛-重氮萘醌正性抗蚀剂溶解抑制机理   总被引:2,自引:0,他引:2  
本文综述了酚醛-重氮萘醌正性抗蚀剂的溶解抑制机理,主要包括(1)分子间氢键作用机理;(2)偶联反应机理;(3)两步即静态、动态溶解抑制机理;(4)表面沉积溶解抑制机理;(5)酚醛树脂的分子溶解及相关的抑制机理.  相似文献   

10.
重氮萘醌系正性抗蚀剂“增感”的进展   总被引:2,自引:1,他引:1  
重氮萘醌系正性抗蚀剂“增感”的进展余尚先*顾江楠童晓方慧聪(北京师范大学化学系,北京100875)关键词重氮萘醌,正性抗蚀剂,多酚化合物,高感度,M/A值控制规律近年来有关重氮萘醌系正性抗蚀剂提高感度的研究文献综述均对应用较为成功的多酚化合物作了较为...  相似文献   

11.
Thiosugars containing a sulfur atom as heteroatom in the sugar ring are highly interesting. In particular, 5-thioaldopyranoses have attracted considerable attention because they exhibit biologically important properties as the substrates for glycosidases also can be developed as potential therapeutical agents, such as antineoplastic, anti-diabetic, antiviral, and antithrombotic agents. In this review, we describe and discuss the advances in synthetic strategies for the preparation of 5-thioaldopyranoses (5-thio-d-hexoses, 5-thio-l-hexoses, 5-thio-d-pentoses and 5-thio-l-pentoses), as well as their spectroscopic NMR data as known to date. The study aims to give readers an easy understanding of thiosugars chemistry and provide a useful guide for carbohydrate chemists.  相似文献   

12.
13.
王相承  袁天平  李建 《应用化工》2011,40(3):486-488,491
介绍了合成N4-乙酰氟胞苷的新工艺。在溶剂中5-氟胞嘧啶∶六甲基二硅胺烷(HMDS)∶三甲基氯硅烷(TMCS)∶四乙酰核糖(摩尔比)=1∶0.8∶0.8∶1,以无水四氯化锡为催化剂,一锅法合成5-氟胞苷,并以甲醇为溶剂直接用乙酐酰化得到N4-乙酰氟胞苷。总收率77%以上。  相似文献   

14.
任洪发 《山东化工》2011,40(5):11-13
呈昧核苷酸二钠包括5’-肌苷酸二钠和5’-鸟苷酸二钠,难以形成良好的结晶体,针对现有研究中存在的问题。对呈味核苷酸二钠结晶工艺进行改进,优化工艺参数。研究发现,采用乙醇为溶析剂,在合适的结晶液浓度和溶析剂添加量的条件下,添加晶种程序降温结晶,有利于提高结晶收率、产品纯度和堆密度。在优化的结晶条件下,呈味核苷酸二钠产品色谱纯度达到99.54%,堆密度达到0.54g/cm3,满足国际市场的要求。  相似文献   

15.
采用贵金属Pt、Pd为活性组分,HZSM-5沸石为载体,制备正丁烷异构化催化剂,在加压连续微反-色谱装置上对催化剂的反应性能进行考察。结果表明,负载Pt的贵金属催化剂在350℃具有较好的活性和选择性,在该温度下,HZSM-5沸石负载质量分数0.3%的Pt时,异丁烷选择性为40.0%,在相同温度下负载质量分数0.3%Pd时,异丁烷选择性为32.9%。  相似文献   

16.
本文合成了2-(5-溴-2-吡啶偶氮)-5-二乙氨基酚(5-Br-PADAP)的Zn,Co,Cu,Ni的4种金属螯合物,利用紫外可见光谱仪和差热-热重分析系统分别研究了5-Br-PADAP及其Zn,Co,Cu,Ni的金属螯合物在溶液态的光谱学性质和热力学性质,并进一步研究了5-Br-PADAP·Ni和5-Br-PADAP·Co薄膜态的透射光和反射光性质。研究发现5-Br-PADAP·Co,5-Br-PADAP·Ni可以作为良好的光信息存储介质材料。  相似文献   

17.
Despite intensive research, glioblastoma remains almost invariably fatal. Various promising drugs targeting specific aspects of glioma biology, in addition to or as an alternative to antiproliferative chemotherapy, were not successful in larger clinical trials. Further insights into the biology of glioma and the mechanisms behind the evasive-adaptive response to targeted therapies is needed to help identify new therapeutic targets, prognostics, or predictive biomarkers. As a modulator of the canonically oncogenic Rho-GTPase pathway, Lipid phosphate phosphatase-related protein type 5 (LPPR5) is pivotal in influencing growth, angiogenesis, and therapeutic resistance. We used a GL261 murine orthotopic allograft glioma model to quantify the tumor growth and to obtain tissue for histological and molecular analysis. Epicortical intravital epi-illumination fluorescence video microscopy of the tumor cell spheroids was used to characterize the neovascular architecture and hemodynamics. GL261-glioma growth was delayed and decelerated after LPPR5 overexpression (LPPR5OE). We observed increased tumor cell apoptosis and decreased expression and secretion of vascular endothelial growth factor A in LPPR5OE glioma. Hence, an altered micro-angioarchitecture consisting of dysfunctional small blood vessels was discovered in the LPPR5OE tumors. Sunitinib therapy eliminated these vessels but had no effect on tumor growth or apoptosis. In general, LPPR5 overexpression generated a more benign, proapoptotic glioma phenotype with delayed growth and a dysfunctional vascular architecture.  相似文献   

18.
以5-硝基苯并咪唑酮为原料,采用水合肼还原制备5-氨基苯并咪唑酮(BI),反应条件温和,安全,环境友好。研究了溶剂对BI合成5-乙酰乙酰氨基苯并咪唑酮(AABI)的影响:在乙酸乙酯中,BI与双乙烯酮反应合成AABI,收率可达89.3%。  相似文献   

19.
5-硝基二氢苊的光氧化作用在无显影气相光刻中起着重要作用。我们通过红外,核磁共振、色质联用等手段对其光氧化产物进行了分析,并合成了有关化合物进行对照,确认5-硝基二氢苊的主要光氧化产物是5-硝基苊、5-硝基二氢苊酮、羟基-5-硝基二氢苊。  相似文献   

20.
Heng Liu  Qiubin Kan 《Fuel》2011,90(4):1515-1521
A Mo-modified catalyst, Mo-IM-5, was prepared for the non-oxidative aromatization of methane, and for comparison, Mo-ZSM-5 was also synthesized for the same reaction. The physical properties and acidities of the samples were characterized by XRD, SEM, BET and IR spectroscopy. Compared with Mo-ZSM-5, the Mo-IM-5 catalyst showed both a higher methane conversion and higher benzene selectivity. In addition, Mo-IM-5 was slightly more stable than Mo-ZSM-5. The catalytic behavior of Mo-IM-5 may be attributed to its unusual two-dimensional 10-member-ring channel system with the character of three-dimensional cavity. Furthermore, the effects of different Si/Al ratios, Mo loadings and temperatures on the catalytic performance of Mo-IM-5 were also investigated.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号